441 related articles for article (PubMed ID: 33031833)
21. Pharmacological Therapy of Pruritus in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Medina-Morales E; Barba Bernal R; Gerger H; Goyes D; Trivedi HD; Ferrigno B; Patwardhan V; Bonder A
J Clin Gastroenterol; 2023 Feb; 57(2):143-152. PubMed ID: 36598806
[TBL] [Abstract][Full Text] [Related]
22. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Xu J; Wang Y; Khoshdeli M; Peach M; Chuang JC; Lin J; Tsai WW; Mahadevan S; Minto W; Diehl L; Gupta R; Trauner M; Patel K; Noureddin M; Kowdley KV; Gulamhusein A; Bowlus CL; Huss RS; Myers RP; Chung C; Billin AN
Hepatology; 2023 Jan; 77(1):20-32. PubMed ID: 35686937
[TBL] [Abstract][Full Text] [Related]
23. Safety of fibrates in cholestatic liver diseases.
Carrion AF; Lindor KD; Levy C
Liver Int; 2021 Jun; 41(6):1335-1343. PubMed ID: 33751787
[TBL] [Abstract][Full Text] [Related]
24. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
25. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
Zhang H; Li S; Feng Y; Zhang Q; Xie B
Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
[TBL] [Abstract][Full Text] [Related]
27. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
28. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis.
Mizuno S; Hirano K; Isayama H; Watanabe T; Yamamoto N; Nakai Y; Sasahira N; Tada M; Omata M; Koike K
J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):766-70. PubMed ID: 26173026
[TBL] [Abstract][Full Text] [Related]
29. Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus.
Düll MM; Wolf K; Vetter M; Dietrich P; Neurath MF; Kremer AE
Front Med (Lausanne); 2021; 8():641163. PubMed ID: 33937284
[No Abstract] [Full Text] [Related]
30. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.
Turner IB; Rawlins MD; Wood P; James OF
Aliment Pharmacol Ther; 1994 Jun; 8(3):337-42. PubMed ID: 7918930
[TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis.
Raszeja-Wyszomirska J; Wunsch E; Krawczyk M; Rigopoulou EI; Bogdanos D; Milkiewicz P
Liver Int; 2015 Jun; 35(6):1764-71. PubMed ID: 25388280
[TBL] [Abstract][Full Text] [Related]
32. Complications, symptoms, quality of life and pregnancy in cholestatic liver disease.
Zakharia K; Tabibian A; Lindor KD; Tabibian JH
Liver Int; 2018 Mar; 38(3):399-411. PubMed ID: 28921801
[TBL] [Abstract][Full Text] [Related]
33. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
34. Editorial: Itching to Know: Role of Fibrates in PBC.
Levy C; Lindor KD
Am J Gastroenterol; 2018 Jan; 113(1):56-57. PubMed ID: 29311728
[TBL] [Abstract][Full Text] [Related]
35. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron.
Schwörer H; Hartmann H; Ramadori G
Pain; 1995 Apr; 61(1):33-37. PubMed ID: 7644246
[TBL] [Abstract][Full Text] [Related]
36. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.
Wolfhagen FH; Sternieri E; Hop WC; Vitale G; Bertolotti M; Van Buuren HR
Gastroenterology; 1997 Oct; 113(4):1264-9. PubMed ID: 9322521
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of pruritus in cholestasis: understanding and treating the itch.
Beuers U; Wolters F; Oude Elferink RPJ
Nat Rev Gastroenterol Hepatol; 2023 Jan; 20(1):26-36. PubMed ID: 36307649
[TBL] [Abstract][Full Text] [Related]
38. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
39. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study.
Vleggaar FP; Monkelbaan JF; van Erpecum KJ
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):688-92. PubMed ID: 18679073
[TBL] [Abstract][Full Text] [Related]
40. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus.
Hegade VS; Pechlivanis A; McDonald JAK; Rees D; Corrigan M; Hirschfield GM; Taylor-Robinson SD; Holmes E; Marchesi JR; Kendrick S; Jones DE
Liver Int; 2019 May; 39(5):967-975. PubMed ID: 30735608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
